ElectroCore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation For Treatment Of Acute Neurological Injury Presented At 2023 World Stroke Congress

Benzinga ·  10/10/2023 20:03

"VANQUISH" Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH)"NOVIS" Clinical Trial (n=150) of nVNS for the acute treatment of Ischemic Stroke will complete recruitment in 2023ROCKAWAY, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from two abstracts being presented at the 15th World Stroke Congress held October 10-12, 2023, in Toronto, Canada on the possible role of nVNS in the treatment of acute neurological injuries.The nVNS research presented at the 2023 World Stroke Congress covers two recently completed

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment